Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer

Abstract We aimed to increase pathologic complete response (pCR) in patients with invasive breast cancer by adding preoperative capecitabine to docetaxel following 5‐fluorouracil, epirubicin, cyclophosphamide (FEC) (with trastuzumab for patients with HER2‐positive disease) and to evaluate 5‐year dis...

Full description

Saved in:
Bibliographic Details
Main Authors: Frankie Ann Holmes, Beth A. Hellerstedt, John E. Pippen Jr., Svetislava J. Vukelja, Rufus P. Collea, Darren M. Kocs, Joanne L. Blum, Kristi J. McIntyre, Minal A. Barve, Barry D. Brooks, Cynthia R. Osborne, Yunfei Wang, Lina Asmar, Joyce O'Shaughnessy
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Cancer Medicine
Subjects:
Breast cancer
capecitabine
FEC
preoperative chemotherapy
trastuzumab
Online Access:https://doi.org/10.1002/cam4.1472
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.1472

Similar Items